Olanzapine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Olanzapine
- Olanzapine: From Schizophrenia/Bipolar Disorder to Benign Paroxysmal Torticollis of Infancy
Olanzapine: From Schizophrenia/Bipolar Disorder to Benign Paroxysmal Torticollis of Infancy
One-Sentence Summary
Olanzapine is a second-generation (atypical) antipsychotic, originally approved for the treatment of schizophrenia and bipolar disorder. The TxGNN model predicts it may be effective for Benign Paroxysmal Torticollis of Infancy, however, no clinical trials or publications currently support this direction, placing this prediction at evidence level L5 (model prediction only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia / Bipolar Disorder |
| Predicted New Indication | Benign Paroxysmal Torticollis of Infancy |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| Philippines Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Olanzapine is a second-generation antipsychotic with broad multi-receptor antagonism, including dopamine D2 and serotonin 5-HT2A receptors. Its efficacy in schizophrenia and bipolar disorder is well established, and the 5-HT2A antagonism it shares with some migraine prophylactic agents forms the theoretical bridge to vestibular conditions.
Benign Paroxysmal Torticollis of Infancy (BPTI) is a rare pediatric migraine variant characterized by episodic, spontaneously resolving head tilting in young children, likely driven by abnormal brainstem and vestibulo-cerebellar circuitry. The speculative mechanistic link posits that Olanzapine’s multi-receptor antagonism may modulate dopaminergic signaling within these circuits — potentially dampening the aberrant sensory processing that underlies BPTI episodes.
However, this connection is purely hypothetical, with no translational preclinical work or clinical observations to support it. The infant population presents additional and severe safety concerns: metabolic effects, extrapyramidal syndrome, and sedation in neonates and infants are poorly characterized for antipsychotics as a class. This TxGNN prediction should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Philippines Market Information
Olanzapine is currently not registered in the Philippines. No product authorizations are on record as of the data cutoff (2026-06-04).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is derived from the TxGNN model alone (L5 evidence) with no supporting clinical trials or published literature. The proposed target population — infants — presents a uniquely high-risk context for an antipsychotic agent, making any risk-benefit assessment impossible without further data.
To proceed, the following is needed:
- Mechanism of action (MOA) data from DrugBank to confirm the D2/5-HT2A pharmacological rationale
- Philippines FDA package insert to assess approved warnings, contraindications, and pediatric use restrictions
- Preclinical studies examining Olanzapine’s effects in vestibular or brainstem animal models relevant to BPTI
- Pediatric safety profile review, particularly for the infant age group
- Consultation with a pediatric neurology specialist before any further development consideration
Note — Additional Predicted Indications with Existing Evidence
Two lower-ranked TxGNN predictions carry L3 evidence and may warrant earlier-stage evaluation:
Rank Indication Score Evidence Decision 2 Agoraphobia 99.47% 7 publications (incl. 1 open-label trial, 2 systematic reviews) Research Question 3 Dysthymic Disorder 99.28% 5 publications (incl. 1 Cochrane review, 1 open-label/pilot RCT) Research Question These indications — particularly olanzapine augmentation for treatment-resistant panic disorder/agoraphobia and second-generation antipsychotic use in dysthymia — have published pharmacological rationale and early-phase clinical observations. They represent stronger near-term repurposing candidates than the top-ranked BPTI prediction, and separate in-depth reports are recommended.
This report is generated for research reference purposes only and does not constitute medical advice. All repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.